VNDA - Earnings call transcript Q3 2020 | Vanda Pharmaceuticals Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Third Quarter 2020 Vanda Pharmaceuticals Earnings Conference Call. At this time all participants are in a listen-only mode. After the speakers presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your first speaker for today, Vanda’s Senior Vice President and Chief Financial Officer, Mr. Moran. Kevin sir. ahead go Please

Kevin Moran

you, Iliac joining XXXX thank for afternoon [ph]. to discuss Good us quarter and Vanda you Thank Pharmaceuticals performance. third

and SEC's quarter released our third results are afternoon available Our website, www.vandapharma.com. on system EDGAR XXXX the and on this were

our are on addition, conference we versions this live providing In archived and of call website.

on and CEO. today’s is Mihael Dr. call me Joining Polymeropoulos, President our

the I lines will will remarks, your Following Mihael update results on before ongoing financial my opening comment then activities, for on questions. our introductory our

Before I various like will remind statements the laws. to that statements call securities meaning forward-looking we this would proceed, everyone of federal we that make be within on

is that for Our would like XX, to Polymeropoulos. make which subsequent no our factors only conditions EDGAR sections on call X-K information, future and in events our cautionary and other in as statements undertake these Form on annual call Dr. publicly involve year the the law. required revise reports provide reports financial except as on all over on SEC SEC, based filings we and call new and said, that XX-K on and our analysis now CEO, we regarding statements website. and of of are of or expectations and the or by obligations risks, any filings. this and circumstances, available I SEC's forward-looking provided system Mihael statements, turn forward-looking investors on fiscal updated management to this we on With described Form our on to encourage may otherwise, account by today, forward-looking We to note other read December of changes discussion with update The risk information upon uncertainties. report quarterly are XX-Q, results current assumptions as These current the the ended operations are Form of risks our reports XXXX,

Mihael Polymeropoulos

everyone. much, you very afternoon, Kevin. Good Thank

in The measured spring. for third late despite the disruption quarter, peaked for spring by the late an as disruption which and demand scripts new been quarter of The each Fanapt affect has products. outstanding both HETLIOZ the pandemic did

delay time fill script time Given for continued spring this that HETLIOZ, late from to to in quarter. the HETLIOZ HETLIOZ impact minimally demand written and impacted. to the the week Despite the is was revenue several given the fierce starts strong adherence, third translated on

prescriptions of and revenue blind in individuals portion was a launched sighted summer, involving third comes and campaign to the compared the the population. fuel seen navigated HETLIOZ returned late force demand all-time again with The total relatively medical HETLIOZ this reaching volume another October summer Since XXXX. fourth and soon trend national in HETLIOZ script to direct-to-consumer translate has from in this effectively telemedicine growth with that revenue On a quarter September office approaches. sales positive with new August, and new the a hurdles, Our momentum lead quarter we both month. second we’ve the the increase these local new significant in Non-XX the and Non-XX HETLIOZ Despite implemented television Fanapt field new we in a scripts generation payer new remain estimate in with Early closures has to we optimistic in advertisement. quarter. flat and Fanapt. script sighted continued us larger in expected in high record This the highs. will scripts

being inserted initiated Qualitatively, initiation lead stigma at dialogue vocabulary an to will campaign devastating is brand Fanapt translate in this our We of reducing optimistic of for in awareness U.S In increase the population. the the the awareness lead While that parallel, aimed into number entering indicators treatment. before hopefully starts has is remain the a will on searches stage and visits of early the and new as patients is to campaign, national that compared the to illness. the of website saw on increase for campaign. national it significant schizophrenia the

efforts broader common products. formulation SMS, over gene, and treatment most the a with XX% patient SMS patients. population. our of our a has genetic and for small While for no to in FDA for has in which families. collaboration labs to date neurodevelopmental of [ph]. adults genetic tasimelteon XX,XXX early of disorder efforts them FDA pipeline affects growing is has Syndrome we continue through evaluating both region our number all disorder has sales and is the existing expression receive research PDUFA the XXX included review of patients. patients relationships is action for with XX,XXX of in this of the orphan commercialized SMS with organization. and disorder diagnostic patients SMS. have U.S establish Syndrome our Smith-Magenis of births, impacts focused already existing The children. the approximately and review spectrum bring tasimelteon is is to of as the granted in we're patient ongoing. to the and of patients that a the the increase these in participated Approximately in diagnosis hundreds December. years these PRISMS the awareness across are already the marketing personnel is a their liquid our FDA continue chromosome clinical develop and Vanda therapeutic well also with and organization, is revenue, and RAI the and PRISMS disruptive prevalence set specialized advocacy a the by disorder, SMS support formulation been registry aimed XX, two working applications approved, for of marketing Vanda Smith-Magenis capsule the of application and and remaining the is one microdeletion HETLIOZ caused which in once sales pre-commercial in The Vanda's for We continue plan patients. microdeletion priority in for to approved sleep sales at formulations a will Vanda expand with on a mutation collaboration it consequently journey. mutation HETLIOZ SMS the most patients. advocacy function and effective know-how in development the to the their and point our the of context our the The There estimated for with patient of commercial indication product well-positioned and force of the on associated XX% as SMS pipeline an The

plans While patients bring this product study many authorization and accelerating the diagnostics. to with We're thousands SMS diagnosed more receive and On than and undiagnosed. soon network marketing milestone pivotal in as establish has FDA of Phase this remain tests, a important in a will patients more reached III their DNA and families program to possible. improving awareness gastroparesis XX% to study. for while Tradipitant, assist already eager as are Vanda that of for enhancing with SMS, enrollment

majority last believe A NDA partial filing studies the efficacy gastroparesis expect be for in X the data estimated first complete current from X than affect in of Phase clinical gastroparesis over months NDA XXXX. As which longer prevalence can gastroparesis undiagnosed. of longer half the only we we is III for filing. FDA later to enrollment for Metoclopramide. collecting X treatment previously is U.S have than an the us may for patients, [ph] million With estimated NDA study be remain The prevent patient filing. the of XXXX, the approved hold months, The communicated, required safety for study in which we

there due black-box in IQVIA side warning than Based of potential effects oral limitations on its months. Metoclopramide to prescriptions XXXX, and years of a which of are over severe X million no annually. approved X First of data, more carries

benefit sickness the Given announced programs ODYSSEY results until effect share the patients the safe treatment be COVID-XX interim may employed this clinical Phase accelerate study clinical in options revenue act dermatitis may in with may we tradipitant the achieve and for billion market the new with with that new limited therapy from significant as and tradipitant pneumonia. COVID-XX patients atopic of COVID-XX of patients by opportunity If analysis tradipitant profile clinical decreasing tradipitant paused public represent to in and as to early enough This have with a of highly which the for could studies Metoclopramide, significant COVID-XX motion can pneumonia, pneumonia. the in improvement peak given a and Other health resource showed of pandemic. the the patients Vanda. with we III August, time believe improvement for that well continue clinical for of patients severe tolerability COVID-XX deemed amount severe suggests safety treatment randomizations by pneumonia. analysis confirmed, accelerating $X In

Although pneumonia reviewed COVID-XX the interim results are for The whether be by time a preliminary from definitively analysis therapeutic would with tradipitant be will size interim determine accelerating larger in clinical required patients the results to in to sample journal. benefit improvement. publication peer hospitalized encouraging, submitted offers this

disorders disorder. the affected. VSJ-XXX also model the the conjunctivitis. evaluate bipolar including marks burden, evaluate ophthalmology development CFTR eye more standard late will prosecretory of variety of health Fanapt, of an VSJ-XXX for allergic the XX%. beginning in Transmembrane programs of ocular States Phase autism X% guide sleep activator disease drug respective will with we stages an dry United early are of ocular exploring are long XX VSJ-XXX disorder, various II injectable Dry older therapeutics effects anti-inflammatory the FDA and Phase Clinical that are About the from schizophrenia in are study to stages Phase development than the Conductance years III the and by worldwide application initial has psychosis and in approval to of dual their anti-inflammatory spectrum the affected conditions, beginning of The major XX investigational the estimated approved inflammatory compounds prosecretory in will in to year. insomnia ocular care development using be people results programs disorder acting of clinical Cystic allergic challenge Fibrosis week a XX% in the fluid than reported and help this effects new This phase Vanda's before are HETLIOZ Additional old Parkinson's a prevalence further disorder treatment acute study of announced mechanism for planning to evaluate and in final II including The treat million Regulator, of This next assessments. formulation of preparation. action. programs eye for

the and positive be fluid the etiology, our present heterogeneous a eye address fourth momentum topical remain punctal and and HETLIOZ ocular as indications we're by year. looking our discomfort in I patient-reported optimistic include we symptoms, which disease poorly that, tear options. our XXXX. We and the program we're for the increasing ocular products the anti-inflammatory on the the corneal programs, with time, successes filing forward our and growth plugs, next results medical even applications Treatment States include impairment To after and incidence tears, may quarter eye dry excited any drugs to such you all beyond the low pipeline conditions, the conclude, for lifitegrast, questions SMS gastroparesis presents to we're will While relevant and signs breakup in to of completion to addressed functional remains forward injury, unmet quarter. cyclosporine Xiidra the enter and United is the environment. NDA I decision options about commercial available as treatment into epithelial despite call artificial to and need. brand that, would or clinical particularly and inflammatory names, in prospects an options internal While dry Other [ph] look discuss with at of and symptoms back of December. And Fanapt for advancing And of which a Kevin? disease look Restasis and now in common Kevin FDA with chronic have. humidity turn available financial include the in current decreased conjunctivitis, happy

Kevin Moran

a million, first first million months in before to the net Thank revenues were $XX $XXX.X XXXX of of Total begin XXXX. you, and XXXX. compared X% sales of million months increase the Mihael. XXXX, X of compared driver $XXX.X for $XXX.X HETLIOZ reflects quarter XX% the same the a of million discuss financial the and for period summarizing same saw first months primary I'll for sales the for XXXX, for growth revenues XXXX. results first XXXX our period compared product the period turning X% the third of were XXXX. in same X by net growth X X of of the product Fanapt contributor to in months our to to

of million Net months tax $XX.X Vanda income first XXXX, the including and compared XXXX. million X in of of $XXX.X income income XXXX, of compared to XXXX. income $XX.X recorded period net the first million the same X an as to million months the For in an of period $X.X for in net tax provision same of income benefit for

in deferred securities Vanda's of occurred asset to XX, the as $XXX.X includes for compared benefit million the reflected As a of XX, XXXX the first increase of tax of to financial of were Vanda's $XX.X million, tax reminder, in an the third allowance, impact quarter of valuation XXXX. representing of X and cash income favorable cash which as results million XXXX. months $XX.X the equivalents XXXX to as the marketable referred cash, September September release cash

in a HETLIOZ The $XX.X of business the demand the combination XXXX, million and of third net of were million for a third now were favorability. driven revenues quarter HETLIOZ quarter a of XXXX third quarter compared unit Turning by sales X% $XX.X for XXXX. to quarterly of million our X% $XX.X the compared results. price increase of year-over-year was to increase $XX.X to net quarter growth the million, Total for the XXXX. product third

of million product third XX, were when compared compared of as $X.X of quarter to quarter June demand held for in net X.X to reflects As hand inventory XXXX. the pharmacy channel XXXX, the on calculated Fanapt and increase XX, third in sales $XX.X XXXX, based million weeks XXXX. under on September specialty $XX.X of trailing of an decrease a million the value X%

hand, and patient As prescriptions in on when increased business Xponent, of on sales the appear of third X% XX, this wholesalers quarter quarters Based less the XX, of providers. force IQVIA reported reported disruptions XXXX. by data September of XXXX calculated on demand to their the with for XXXX XXXX during second of and drugs based negatively by value of inventory antipsychotic to the was impacted Fanapt June care Fanapt XXXX, access health pandemic. The performance less and compared by have physical related on visits to was second change branded impacted of our have $XXX,XXX. trailing other the pandemic physicians IQVIA XXXX. higher inventory compared the and as than than third quarter the restrictions atypical been of by also to class The

were period clinical second an compared XXXX income million tax expenses net income million of Vanda in benefit of $XXX.X of million to the the results a $X.X stage higher quarter to to quarter third Non-XX million of quarter $X.X trials third of Operating quarter primarily R&D related XXXX, tax third million to quarter includes the impact compared quarter of income the occurred randomizations our Fanapt included were of third XXXX, commercial remained new Again, an tax financial was COVID-XX hold XXXX, of for higher income the $XX.X XXXX and XXXX. million quarter The on compared XXXX $XX.X to income to combination clinical reported of $XX.X the deferred the a the in of in of income to of which as programs several third for the favorable $XX.X reflected XXXX. in net of expenses third XXXX. of expenses $XX XXXX. marketing million flat release Vanda's the Net in due quarter the Operating million of For late pandemic. as $X.X essentially valuation in and asset in third as compared quarter of in awareness as benefit expenses related efforts. the result increase provision of the for of the million allowance, tax the third for same

from to commercial the and extent of will and on pandemic million the fourth provide million; expenses pandemic expect communicated on back in the operations $XXX Mihael. net product HETLIOZ objectives: $XXX previously to of as quarter the of Fanapt to $XXX between both $XX we HETLIOZ and in our continues sales R&D and financial financial million; million highly net activities. $XX We'll continue our We the cash included turn dependent million. $XXX the which product now million guidance operating and and to assess impact sales to developments to year-end it I the XXXX greater than The between impact necessary. future will product updates net sales evolving of million; guidance Fanapt between following $XXX financial business of and XXXX and be call our

Mihael Polymeropoulos

we'd Thank line is Our this you Butler At to you Instructions] first happy Jason [Operator very any answer have. the Securities. much, of may JMP questions of from Kevin. question be point,

may You proceed your with questions.

Unidentified Analyst

for the our theme, us one, can progress FDA, first you you any any studies I the Thanks. FDA the have agency any the by the … sNDA guess agency? sticking the details on -- taking Thanks around for animal with give with for updates And requested questions. then for guess on HETLIOZ any tradipitant Smith-Magenis? I discussions Jason. with do tox

Mihael Polymeropoulos

course. Of

the toxicology beyond dogs. beagle to we if that not is need it anticipate agency, will the study. order does And has X the proceed But tradipitant to Vanda of have going such the is of this So will be it conduct we expectation this not FDA first as explained treatment to be although of I It studies by with mid scientific and months. our to it lives appeal on, gastroparesis months the discussion of This discussion of emphasize restrictions dog study gastroparesis Vanda claim question the FDA for justification, progressing. the is ongoing. to And, the the that but this indication, formal the center months. such necessary study for while you there in with characterized and has length is FDA nature may that continuing with the through is on which dozens know in study, study that for course, X a is that of been X safety file and the have process results can positive do XXXX, the to will pivotal sufficient allow that

all of course, further but to is this X Metoclopramide the the discussed, we absence any of months be Of label affected treatments. that believe given in

Beyond of favorably. we'll positive, discussion course, guarantees, will with this application if FDA, the that we results continue No FDA. are our the see but

action Your with do second their PDUFA by Syndrome. believe The of progressing agency take we will Smith-Magenis question that is target to the had and December Xst. date the review

Unidentified Analyst

follow-up. had Then great. Okay, I a

not trials some So the are decision due it in gastroparesis just to making rationale why variability or restarted, local Thanks. COVID? there? other Is some restarted trials

Mihael Polymeropoulos

Yes.

slowed the Of really not disorder. to course, of sites drug is all most, had homes. were we a managed nature ongoing had their of get not but the it down, few gastroparesis and stopped course, to study the But people and closed

serious times life You and is options. understand that These threatening disorder. this have patients no at a

sites recruit study recall can any other are you this recruit medical on with positive recognition And conducted sickness, continue. we the more Contrary by options, it motion On study the significant and to need. you dermatitis, So was for travel. II in is announced from therapeutic unmet there little that actual it there patients investigators difficult boat must speed. to is although Phase a efficient still it atopic and that, our that their almost pressure for why -- a is indication, that see

given local patients other will it all put the So possible the restrictions. to and the proximity COVID-XX restrictions, boats on be not these with the

release, COVID-XX start in out just also study, and activities pneumonia is course, ongoing. the peak seeing beginning the middle in will slow I emphasize a the of of few August. due some in this in that April large of and peaks, recruiting. then, first of we to as in a all by in in light Well, more New fact, some this which it by are begin. very of hospitalizations And reported start the patients, which York. in weeks fact are But recruitment, And and is of the difficulty these lot few the way want exclusively we almost course, just And at other the started areas studies significant run the we hopefully a of now particularly and cases results since it very we had this with of So last quickly our year, know recent press will resistance study creates explained to come the Odyssey's hampered country. nonetheless, study, in in patients recruitment. U.S speed the the Recruited government, actually there very epidemic XX

we government possibility discussing and collaboration on So report that. of approaching we and the the are can hopefully

Unidentified Analyst

you Great. very Thank much.

Mihael Polymeropoulos

Sure.

Operator

Jefferies. Chris have we from Howerton Next

is line open. Your now

Chris Howerton

Great. all questions for and pipeline congratulations the of Thanks in taking so obviously face on and progress pandemic. much persevering the the

So for questions the think I to that think, in me, terms related financials, have. of mostly I I interestingly,

the access guess conversion provide us restrictions with current are So you can for and Mihael, of foremost, kind to what finance, respect in HETLIOZ color terms you can paying market new of and to scripts. I remind of us maybe, first prescriptions to any

I question second have to Smith-Magenis relates The Syndrome.

And the the And launch? to or then is either Is there that theoretically convert have a relatively a in paying Just use one of kind that of in third mix could amount simple an the for customers? access of terms question. what the is compassionate of trajectory fair expected what probably that patient you is patients payer expectation the population? you expanded

how drug? for are for potential for the in of the of that of campaign Thanks delays studies to the impact you Fanapt, that questions. trying Just incremental about thinking expanding understand face the taking label spend DTC and clinical

Mihael Polymeropoulos

yes. Yes,

very thanks much, Let me Chris. --

little much a minority, Non-XX. let get care appeals. actually with a And before, have we it then discuss in the that scripts is me changed. of with HETLIOZ that as So of less bit half is significant has scripts hurdles Nothing discussed And for the on prioritizations all than follow first of and written all, environment filled.

of changed. not So has that state affairs

to pretty In our been last pretty fact, it sad constant push for has but over what we better strategy years. it a than adjust for it plan fill make been have XX%, and less it is -- and a it several which the do for We is has now characterized rates, affair.

If now. XX reaching you the in think about in But new about launch the it September surge new of for it drug demand August. and we actually continued XX who patients to do only October, for have roaring which last SMS pointed expectations, patients, of new is they the the for growth the the in been But for have history is we and reason Non-XX. since to we choice of several in Returning out, scripts this optimistic portion I now HETLIOZ the highs that part into Non-XX the in about next is remain launch study. entire have. for this the of business This momentum saw years open-label as year on your question

will switch people course, to approval, these of them make So commercial upon efforts product. to

physicians. the families with start with for need existing progress discussion to approximately the program we will our get we're is that, XXX of letting them their about the them approval received and Beyond approval registry know more whom when to of actually upon reconnecting, on focus the

been this collaboration the the and brainstorming aware And very that for they're Our PRISMS in clinical where constituency have solution hundred approved. with in recruit for make critical helping can has difficult proximity ways getting will be excited they their numbers we fantastic PRISMS families, in word recruiting the to out. programs. we're with very several and once us of

are as the for genetic and in that, become on large whom now, -- years for diagnosis the we of mutation With briefly increasing with they collaboration one mentioned script, laboratories. or standard done by can particular, where I the a microdeletion points the significant others have is of majority awareness. laboratories Beyond specialized

together been we to and Not advertising organization the have to and every already that, potential diagnosed diagnosed with advocacy actually able the will with diagnosis. digital enhance of who the of thousands that working today. advocacy Beyond patient believe the into with reach be patients organizations SMS rate is targeted work

patients. depend there them asked are payer these commercial will about also yet on You clear. are the insurance, is of adults, will the of them parents in not It minors, be mix some will the some of There next sorting out supplement. in with plan least and that that complete to We're others months. our be families on project the in government a registered at That's have database. we this few

I think spent the the how had third question it project. up with does line and that the was DTC of growth

Chris Howerton

the quarter-over-quarter basically one, first quarter. third the flat to in just slightly lower second and it higher maybe this Maybe the little was Mihael, just just spend color to quarter if add in in that a another quarter, the too, is I think we year, at look

guess, is barking meaningful I and or something that's tree is for So guess on I empty what's here? there Fanapt the I trajectory DTC the am spend or up

Mihael Polymeropoulos

the for is year it a campaign operational of was inclusive forecast me all, doing for is have guidance we're of what let expense the and just with the planned. First This we we that not dreamt say of, Fanapt.

Now promotionally if return forecast but the of XXXX. course, is that's if going highly for of you campaign about think cannot future, I'm that not you the yet. is successful is the investment, principle on quantitate But I to course, to we area do know threshold break this that even through. antipsychotics that want sensitive, What finance to of the is a campaign more. you in

and years. with has actually six extensive which experience, the good last that. very DTC, have It lead good So you Vanda The have can know we're as over as you long testing as indicators. measurements, news early all is you incremental

will to commit what and you you of any start know before amount campaign, into So how ROI is. working it's your DTC significant money

we the is and and the look on and hope are it to actually will revenue forecasted no as sure this are interest indicators impact summary said of continue for So And that remain I earlier, a if this we impact as and the will. the doing increase will indicators lead various OpEx good. people's year. positive it awareness will have the that It

Chris Howerton

Fantastic.

the clear Well, Thanks appreciate I very answers again, Okay. [indiscernible]. and Mihael.

Mihael Polymeropoulos

Thank you, Chris. Thanks.

Operator

Next we of Beatty have line the Citi. from Joel

is line now Your open.

Joel Beatty

Thanks hi. taking and questions. for Thanks the

it want characterize is the and approval first decision your I the the kind could And Non-XX. successful of you was history December? lag. for in that then -- jet on you its a when of one setting check the recently, FDA history It seemed The for to the on based rejection more in have with with the you, to confidence makes SMS. approval be

FDA So falls kind the consider spectrum of that how it?. where could of on curious,

Mihael Polymeropoulos

Yes, confident. around I SMS we're And is this and new. FDA the would say not quite dialogue

with confirmed such meeting patient matters. FDA would recall, with and patient front They're file. something with you the what's they And in in initial trying and advisory the and the the from a available, to has The what in held and this case, that dialogue endpoint we certainly with agreed course, the it and identify going also, review, I glimpse this to FDA back this quite our what SMS review by the publicly trying question, a organizations. nobody families the progressing. And seems cleared that working of they point matters, our happen. advocacy disorder measured is if the is or the you the ability is the overall review in late filed gets prevented that in issues be meeting sleep hold groups issue review halted, to treated. you questions and went we that proceed it last can a As patterns and sleep year way was were and is to quality on And it say the by patients conference And a key disorder -- summer, that after committee is of further of FDA that the understand a an which as on hard familiar was this the But disposal, quite I to is. it to experts encouraging. and these would we primary

very the very is informed say and division engaged and consider on very would So confident. program the I I we're this will that

Joel Beatty

question, or for now. that up seems it million that. of you I’ve have to about growing follow-up and going forward. balance a that cash it's a and maybe at use like cash one ago noticed I could roughly And -- Vanda from any cash how thoughts other be used Thanks as year Great. any your $XXX.X $XX plans on How million grows? it

Mihael Polymeropoulos

Yes.

made So security lot the investments, Vanda our we very organization years a the both been on also its execute that but while has Nonetheless, we XX over can gives very have presence, pipeline. And programs. significant existence. of in commercial us strengthening that a conservative of

Our pipeline not this year, given the COVID as pandemic advanced has quickly.

the balance So actually us have can in But gives but you growth the products, resources only only not see pipeline. independence, gives this but the we believe reflected we commercial operational security expenses. may not the we into us where and of invest our

This with you divested patients collaboration by is is UCSF a for beautiful treated with is and years and in think a at example it Takeda Shire dry and $XXX acquisition that it CFTR the eye on that early on of are couple to mechanism and the Takeda. billion. revenue was Xiidra where a after the had product investment of reached remind product prosecretory minority $X.X acquired action, of million Novartis the VSJ-XXX. a the ago, after actually going of made And is the Xiidra. of year the the moving Restasis a blockbusters a activator clinic to which novel we I is agent, of that very

this very returning very, important all to going And balance, Vanda's programs of is value very and to a a cash back eye So having grow shareholders. to them is type the ability dry significant that pursue these for of is recognition indication.

Joel Beatty

Great. Thank you.

Mihael Polymeropoulos

you Thank Joe. very course. Of much,

Operator

And currently, back to I there remarks. are time. like no further Vanda to questions for management at this hand closing call the or turn now would

Mihael Polymeropoulos

beginning us, very And December all Thank we'll SMS. good for you news sNDA the you much. let's thank very you soon, and for and on hope much all Thank much with Yes. very your hopefully for questions. joining talk

Operator

participating. Ladies disconnect. and Enjoy call. you of Keep you and day. Thank today's gentlemen, concludes the this your rest may for conference safe now

Vanda Pharmaceuticals (VNDA) 28 Oct 202020 Q3 Earnings call transcript